Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SUPN 
Supernus Pharmaceuticals Inc (SUPN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: SUPN (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $43
1 Year Target Price $43
| 2 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 29.33% | Avg. Invested days 45 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.39B USD | Price to earnings Ratio 37.12 | 1Y Target Price 43 |
Price to earnings Ratio 37.12 | 1Y Target Price 43 | ||
Volume (30-day avg) 5 | Beta 0.74 | 52 Weeks Range 29.16 - 43.62 | Updated Date 08/15/2025 |
52 Weeks Range 29.16 - 43.62 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 1.15 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate 0.4767 | Actual 0.9057 |
Profitability
Profit Margin 9.7% | Operating Margin (TTM) 6.73% |
Management Effectiveness
Return on Assets (TTM) 2.39% | Return on Equity (TTM) 6.38% |
Valuation
Trailing PE 37.12 | Forward PE 20.16 | Enterprise Value 1902938126 | Price to Sales(TTM) 3.6 |
Enterprise Value 1902938126 | Price to Sales(TTM) 3.6 | ||
Enterprise Value to Revenue 2.82 | Enterprise Value to EBITDA 10.76 | Shares Outstanding 56073100 | Shares Floating 48501539 |
Shares Outstanding 56073100 | Shares Floating 48501539 | ||
Percent Insiders 4.21 | Percent Institutions 109.2 |
Upturn AI SWOT
Supernus Pharmaceuticals Inc
Company Overview
History and Background
Supernus Pharmaceuticals, Inc. was founded in 2005. It is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Significant milestones include the FDA approval and launch of several CNS-focused products.
Core Business Areas
- Neurology: Focuses on developing and commercializing treatments for neurological disorders, including epilepsy and migraine. Key products include Trokendi XR and Oxtellar XR.
- Psychiatry: Focuses on developing and commercializing treatments for psychiatric disorders, including ADHD. Key products include Qelbree.
Leadership and Structure
The company's leadership team consists of seasoned executives in the pharmaceutical industry. The organizational structure is typical of a publicly traded biopharmaceutical company, with functional departments such as R&D, commercial, and finance.
Top Products and Market Share
Key Offerings
- Qelbree: A non-stimulant medication for ADHD. Competitors include stimulant-based medications (e.g., Adderall, Ritalin) and other non-stimulant options (e.g., Strattera). Revenue from Qelbree was a major driver for Supernus in 2023.
- Trokendi XR: An extended-release formulation of topiramate used to treat epilepsy and migraine. Competitors include other antiepileptic drugs and migraine medications. Facing generic competition.
- Oxtellar XR: An extended-release formulation of oxcarbazepine used to treat epilepsy. Competitors include other antiepileptic drugs. Facing generic competition.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high R&D costs, long development timelines, and significant regulatory hurdles. The CNS therapeutics market is large and growing, driven by an aging population and increasing awareness of mental health disorders.
Positioning
Supernus positions itself as a specialty pharmaceutical company focused on CNS disorders, with a strategy of developing differentiated products and building a strong commercial infrastructure.
Total Addressable Market (TAM)
The TAM for CNS therapeutics is estimated to be billions of dollars annually. Supernus aims to capture a significant share of this market through its existing portfolio and pipeline products.
Upturn SWOT Analysis
Strengths
- Focus on CNS disorders
- Established commercial infrastructure
- Portfolio of approved products
- Strong revenue growth from Qelbree
Weaknesses
- Reliance on a few key products
- Facing generic competition for Trokendi XR and Oxtellar XR
- High debt levels
- Intangible Asset Risk
Opportunities
- Expanding indications for existing products
- Developing new CNS therapies
- Acquiring complementary assets
- Geographic expansion
Threats
- Regulatory challenges
- Competition from other pharmaceutical companies
- Pricing pressures
- Patent expirations
Competitors and Market Share
Key Competitors
- TEVA
- VTRS
- JAZZ
Competitive Landscape
Supernus competes with both large pharmaceutical companies and smaller biotech firms in the CNS therapeutics market. Its competitive advantage lies in its focus on differentiated products and its established commercial infrastructure.
Growth Trajectory and Initiatives
Historical Growth: Supernus has experienced significant revenue growth in recent years, driven by the launch and uptake of Qelbree.
Future Projections: Analysts expect continued revenue growth, driven by increased Qelbree sales and potential new product launches. Profitability is expected to improve.
Recent Initiatives: Recent initiatives include expanding the sales force for Qelbree, conducting clinical trials for new indications, and exploring potential acquisitions.
Summary
Supernus Pharmaceuticals is a growing biopharmaceutical company focused on CNS disorders. Qelbree is driving revenue growth, but the company faces generic competition for older products. Strategic acquisitions and pipeline development are key to future success, but debt levels need to be closely monitored. The success of Qelbree, while encouraging, has to be tempered by debt management.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Analyst Reports
- Company Website
- Third-party financial data providers
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is estimated and may not be precise. Financial data is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Supernus Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Rockville, MD, United States | ||
IPO Launch date 2012-05-01 | Founder, President, CEO, Secretary & Director Mr. Jack A. Khattar M.B.A. | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 674 | Website https://www.supernus.com |
Full time employees 674 | Website https://www.supernus.com | ||
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes products for the treatment of central nervous system (CNS) diseases in the United States. The company offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS; and SPN-446, a preclinical product for CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.